Skip to content

Exosomal PD-L1 Level in plasma as a predictive marker for diagnosis and clinical correlation in non-small cell lung cancer

Exosomal PD-L1 Level in plasma as a predictive marker for diagnosis and clinical correlation in non-small cell lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20210808001
Enrollment
70
Registered
2021-08-08
Start date
2021-08-07
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer Biomarker Exosome liquid biopsy pathology PD-L Non-small cell lung cancer

Interventions

Non-small cell lung cancer patients with confirmed diagnosis by tissue biopsy
Diagnostic
Non-small cell lung cancer patients

Sponsors

Chulalongkorn University Systems biology center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older 2. Body weight > 30 kg 3. NSCLC patients with confirmed diagnosis by tissue biopsy 4. Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens 5. Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder or superior vena cava syndrome) 3. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomisation, unstable arrhythmias or unstable angina i. Patients with a known left ventricular ejection fraction (LVEF) < 40% will be excluded 4. Severe infections within 4 weeks after receiving treatment including but not limited to hospitalisation for complications of infection, bacteraemia or severe pneumonia 5. Known active or untreated central nervous system (CNS) metastases 6. Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome

Design outcomes

Primary

MeasureTime frame
progression-free survival at which tumors recurrence is detected time scale

Secondary

MeasureTime frame
correlation between exosomal PD-L1 and tumor PD-L1 Before resection of tumor percentage of expression and levels of exosomal PD-L1,dynamic of exosomal PD-L1 change before and after resection of tumor ELISA,difference of the level of exosomal PD-L1 levels between each stage of non-small cell lung cancer before resection of tumor ELISA,correlation between clinical variables and exosomal PD-L1 before resection of tumor ELISA

Countries

Thailand

Contacts

Public ContactPanot Sainamthip

Faculty of medicine Chulalongkorn university

Panot.s@chula.ac.th0955974249

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026